A Double Blind, Randomized, Placebo-controlled Study to Evaluate, Safety, Tolerability, Efficacy and Preliminary Dose-response of BAF312 in Patients With Active Dermatomyositis (DM)
Phase of Trial: Phase II
Latest Information Update: 23 Jan 2019
Price : $35 *
At a glance
- Drugs Siponimod (Primary)
- Indications Dermatomyositis
- Focus Therapeutic Use
- Sponsors Novartis
- 23 Jan 2019 Status changed to discontinue.
- 25 Jan 2016 Planned end date changed from 1 Apr 2017 to 1 Feb 2016, as reported by ClinicalTrials.gov.
- 25 Jan 2016 Planned primary completion date changed from 1 Apr 2017 to 1 Feb 2016, as reported by ClinicalTrials.gov.